The link between increased Desulfovibrio and disease severity in Parkinson’s disease

Nie, Shiqing; Jing, Zhongwang; Wang, Jichen; Deng, Ye; Zhang, Yingshuang; Zheng, Yi; Ge, Yuan

doi:10.1007/s00253-023-12489-1

Cited by 6 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the concentration of these bacterial species correlated with the clinically observed severity of PD ( p < 0.01). Very recent Chinese research has confirmed these results [ 88 ], which suggests that Desulfovibrio bacteria take part in the pathogenesis of PD, which opens a new avenue for patient classification and treatment.…”

Section: Discussionmentioning

confidence: 77%

Parkinson’s Disease: A Tale of Many Players

Pauwels¹,

Boer²

2023

Med Princ Pract

View full text Add to dashboard Cite

In 2020, more than 9 million patients suffering from Parkinson’s disease (PD) were reported worldwide, and studies predict that the burden of this disease will grow substantially in industrial countries. In the last decade, there has been a better understanding of this neurodegenerative disorder, clinically characterized by motor disturbances, impaired balance, coordination, memory difficulties, and behavioral changes. Various preclinical investigations and studies on human postmortem brains suggest that local oxidative stress and inflammation promote misfolding and aggregation of alpha-synuclein within Lewy bodies and cause nerve cell damage. Parallel to these investigations, the familial contribution to the disease became evident from studies on genome-wide association in which specific genetic defects were linked to neuritic alpha-synuclein pathology. As for treatment, currently available pharmacological and surgical interventions may improve the quality of life but do not stop the progress of neurodegeneration. However, numerous preclinical studies have provided insights into the pathogenesis of PD. Their results provide a solid base for clinical trials and further developments. In this review, we discuss the pathogenesis, the prospects, and challenges of synolytic therapy, CRISPR, gene editing, and gene- and cell-based therapy. We also throw light on the recent observation that targeted physiotherapy may help improve the gait and other motor impairments.

show abstract

Section: Discussionmentioning

confidence: 77%

Parkinson’s Disease: A Tale of Many Players

Pauwels¹,

Boer²

2023

Med Princ Pract

View full text Add to dashboard Cite

show abstract

Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes

Palacios

Wilkinson²,

Bjørnevik

et al. 2023

Annals of Neurology

View full text Add to dashboard Cite

ObjectivePrior studies on the gut microbiome in Parkinson's disease (PD) have yielded conflicting results, and few studies have focused on prodromal (premotor) PD or used shotgun metagenomic profiling to assess microbial functional potential. We conducted a nested case–control study within 2 large epidemiological cohorts to examine the role of the gut microbiome in PD.MethodsWe profiled the fecal metagenomes of 420 participants in the Nurses' Health Study and the Health Professionals Follow‐up Study with recent onset PD (N = 75), with features of prodromal PD (N = 101), controls with constipation (N = 113), and healthy controls (N = 131) to identify microbial taxonomic and functional features associated with PD and features suggestive of prodromal PD. Omnibus and feature‐wise analyses identified bacterial species and pathways associated with prodromal and recently onset PD.ResultsWe observed depletion of several strict anaerobes associated with reduced inflammation among participants with PD or features of prodromal PD. A microbiome‐based classifier had moderate accuracy (area under the curve [AUC] = 0.76 for species and 0.74 for pathways) to discriminate between recently onset PD cases and controls. These taxonomic shifts corresponded with functional shifts indicative of carbohydrate source preference. Similar, but less marked, changes were observed in participants with features of prodromal PD, in both microbial features and functions.InterpretationPD and features of prodromal PD were associated with similar changes in the gut microbiome. These findings suggest that changes in the microbiome could represent novel biomarkers for the earliest phases of PD. ANN NEUROL 2023

show abstract

The link between the gut microbiome, inflammation, and Parkinson’s disease

Nie,

2023

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The link between increased Desulfovibrio and disease severity in Parkinson’s disease

Cited by 6 publications

References 58 publications

Parkinson’s Disease: A Tale of Many Players

Parkinson’s Disease: A Tale of Many Players

Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes

The link between the gut microbiome, inflammation, and Parkinson’s disease

Contact Info

Product

Resources

About